{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-016272","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.697257+00:00","generated_at":"2026-06-21T07:34:54.634316+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ENDRA Life Sciences to effect 1-for-20 reverse stock split on Dec 9, 2022","bullets":["Stockholders approved the 1-for-20 reverse split at a special meeting on November 29, 2022.","Effective 12:01 a.m. ET Dec 9; every 20 outstanding shares become 1 share; fractional shares rounded up.","Authorized shares remain 80M; exercise price and share counts for outstanding options proportionally adjusted.","Common stock will trade on Nasdaq on a split-adjusted basis under symbol NDRA; new CUSIP 29273B302."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-016272","json":"https://secwatch.observer/filing/0001654954-22-016272.json","markdown":"https://secwatch.observer/filing/0001654954-22-016272.md","text":"https://secwatch.observer/filing/0001654954-22-016272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/0001654954-22-016272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:34:54.634316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"300c581492471b53a35a779b8655ff0fb7f513e0","claim":"ENDRA Life Sciences Inc.: Effected a 1-for-20 reverse stock split of common stock through a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation (effective 2022-12-09).","evidence_excerpt":"On December 8, 2022, ENDRA Life Sciences Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (Eastern time) on December 9, 2022 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/0001654954-22-016272-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-12-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}